Fewer than one in 10 individuals who could benefit from GLP-1 drugs like Wegovy are able to get them, warns the global health agency as it publishes its first advice on the therapies.
With in excess of 1,000,000,000 people worldwide currently classified as obese, it is urging increased and just availability to GLP-1 medication.
Per projections, more than two billion are projected to be living with obesity by 2030 unless action is taken.
"Our latest guidelines recognises that excess weight is a lifelong illness that can be addressed with comprehensive and ongoing care," remarked its chief Tedros Adhanom Ghebreyesus.
Substantial prices, constrained manufacturing, and supply-chain constraints are significant hurdles to broad access to the jabs that can assist patients in reducing significant body mass, explains the organization.
Skinny Jab Scarcity
Even under the current most optimistic case, the supply of GLP-1 therapies could only cover about 100 million people – less than 10% of the global need, as stated by the health organization.
The advice calls on nations and manufacturers to widen availability, through strategies including patent sharing.
Exclusive production rights on semaglutide – the primary ingredient of the drug Wegovy – is scheduled to end in several nations in 2026.
The Way Obesity Jabs Function
GLP-1 drugs replicate a body's own hormone to slow digestion, reduce hunger and increase satiety so people reduce food intake.
Patients usually see weight reduction within a few weeks of starting on the weekly injections.
Research points to people may regain a significant portion a year later of halting the drug, because their normal food cravings come back.
Being carrying excess weight increases your risk for contracting diseases, like diabetes, heart disease, stroke, and some malignancies.
Obesity concerns individuals in countries worldwide and was responsible for 3.7 million fatalities worldwide in 2024, per the health agency.
